This message was sent to ##Email##
|
|
|
|
|
AST
There exists a potential for donor-derived Zika virus infections with unknown consequences for recipients. The following is guidance developed by the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC) with collaboration from the AST and ASTS and provides expert advice on donor screening and recipient testing for Zika virus.
READ MORE
AST
Disparities in access to health care due to race and/or socioeconomic status remain an unfortunate reality in today’s society. AST member Dr. Win Williams recently published an outstanding body of work that demonstrates how an organ allocation variance related to A2 and B blood types is able to promote equity in organ allocation. He wrote the latest AST blog post on this specific approach to remediating disparities in access to transplantation.
READ MORE
AST
The AST is pleased to announce a new Resident/Student American Transplant Congress (ATC) Travel Award Program, targeted at residents and students who have expressed interest in obtaining more exposure to the field of transplantation before committing to training in transplantation.
READ MORE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
AST
Feb. 10, 2016 | 11 a.m. EST | Online activity
For more information: https://www.myast.org/education/astajt-journal-club
AST
Feb. 16, 2016 | 2 p.m. EST | Online activity
For more information: https://www.myast.org/education/webinars/t3
 |
|
- predictions for your next five SRTR reports
- customized, personal wait list management
- data validation that impacts your "expected" number
- data-based appeal assistance for centers facing regulatory issues
- fQAPI dashboard analytics with one click
|
|
AST
Feb. 18, 2016 | 11 a.m. EST | Online activity
For more information: https://www.myast.org/education/astajt-journal-club
AST
Feb. 25-27, 2016 | Phoenix, Arizona
For more information: http://2016.ceot.myast.org/
The shortfall between the demand and the availability of organs for transplantation has never been greater. Tackling this mismatch requires a multifaceted approach, which addresses issues at all levels. CEOT 2016 focuses on how the effects of redistricting, the possibility of incentives, and how the use of marginal donors can and will impact the donor organ shortage problem.
AST
June 11-15, 2016 | Boston, MA
For more information: http://atcmeeting.org/
The Federation of Clinical Immunology Societies
June 22-25, 2015 | Boston, MA
For more information: https://www.myast.org/meetings/focis-2016
Nature Biotechnology
Transplantation of pancreatic progenitors or insulin-secreting cells derived from human embryonic stem cells (hESCs) has been proposed as a therapy for diabetes. We describe a seven-stage protocol that efficiently converts hESCs into insulin-producing cells. Stage (S) 7 cells expressed key markers of mature pancreatic beta cells, including MAFA, and displayed glucose-stimulated insulin secretion similar to that of human islets during static incubations in vitro.
READ MORE
The New England Journal of Medicine
In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated with similar patient and graft survival and significantly improved renal function in kidney-transplant recipients. Here we present the final results from this study.
READ MORE
Nature Medicine
The transplantation of glucose-responsive, insulin-producing cells offers the potential for restoring glycemic control in individuals with diabetes. Pancreas transplantation and the infusion of cadaveric islets are currently implemented clinically, but these approaches are limited by the adverse effects of immunosuppressive therapy over the lifetime of the recipient and the limited supply of donor tissue.
READ MORE
American Journal of Transplantation
Organ transplantation from ABO blood group–incompatible (ABOi) donors requires accurate detection, effective removal and subsequent surveillance of antidonor antibodies. Because ABH antigen subtypes are expressed differently in various cells and organs, measurement of antibodies specific for the antigen subtypes in the graft is essential. Erythrocyte agglutination, the century-old assay used clinically, does not discriminate subtype-specific ABO antibodies and provides limited information on antibody isotypes.
READ MORE
Liver Transplantation
Patients with T1 hepatocellular carcinoma (HCC; 1 lesion less than 2 cm) are currently not eligible for priority listing for liver transplantation (LT). A common practice is to wait without locoregional therapy (LRT) until tumor growth occurs from T1 to T2 (1 lesion 2-5 cm or 2-3 lesions less than or equal to 3 cm) to be eligible for listing with Model for End-Stage Liver Disease exception. We aimed to evaluate the intention to treat outcome of the "wait and not ablate" approach for nonresection candidates with T1 HCC until tumor growth to T2.
READ MORE
|
|
|
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
